Sam Chun Dang Pharm Co., Ltd. (000250) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sam Chun Dang Pharm Co., Ltd. (000250:KRX), powered by AI.

Current Price
₩648,000
P/E Ratio
-1366.3
Market Cap
15.2T
Sector
Common Stock
What is the Sam Chun Dang Pharm Co., Ltd. stock price forecast?

Sam Chun Dang Pharm Co., Ltd. is currently trading at ₩648,000. View real-time AI analysis on Alpha Lenz.

What is Sam Chun Dang Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for Sam Chun Dang Pharm Co., Ltd. on Alpha Lenz.

What is Sam Chun Dang Pharm Co., Ltd.'s P/E ratio?

Sam Chun Dang Pharm Co., Ltd.'s P/E ratio is -1366.3.

Sam Chun Dang Pharm Co., Ltd.

₩648.00K
KRX000250
Ask about Sam Chun Dang Pharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Sam Chun Dang Pharm Co., Ltd. trades at a P/E of -1366.3 (undervalued) with modest ROE of -4.5%.

Ask for details

Company Overview

Sam Chun Dang Pharm Co., Ltd. is a notable pharmaceutical company involved in the research, development, and production of various healthcare solutions. Founded in South Korea, the company focuses on creating a diverse array of pharmaceutical products that cater to the healthcare needs of a broad spectrum of patients. Their portfolio includes over-the-counter drugs, prescription medications, and a range of health supplements, demonstrating their commitment to improving public health and optimizing therapeutic outcomes. By participating actively in the pharmaceutical industry, Sam Chun Dang Pharm Co., Ltd. contributes significantly to the accessibility and availability of essential medications across regional and global markets. The company consistently invests in innovation and manufacturing excellence, ensuring compliance with international regulatory standards and thereby enhancing its market reputation. Its role in the healthcare sector is pivotal, as it addresses critical medical needs and supports the overall advancement of medical sciences.

CEO전인석
SectorCommon Stock
IndustryCommon Stock
0

Company Statistics

(FY 2024)

Profile

Market Cap₩15,200.44B
Revenue₩210.92B
Shares Out23.46M
Employees0

Margins

Gross47.25%
EBITDA8.54%
Operating1.25%
Pre-Tax5.23%
Net-2.41%

Valuation

P/E-1366.25
P/B56.05
EV/Sales70.71
EV/EBITDA829.37
P/FCF-763.65

Growth (CAGR)

Rev 3Yr8.04%
Rev 5Yr2.48%
Op Inc 3YrN/A
Op Inc 5Yr-36.31%
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-1.09%
ROE-4.49%
ROIC2.46%

Financial Health

Cash & Cash Equivalents₩105.58B
Net Debt₩64.78B
Debt/Equity48.76%
Interest Cov88.94
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Sam Chun Dang Pharm Co., Ltd. (Common Stock) Stock Forecast & Analysis ₩648,000 | Alpha Lenz